Home › Type 2 Diabetes › NCT04024631
Phenotyping Genetic Risk for Type 2 Diabetes
RecruitingHealthy volunteers welcome
Phenotyping Children and Adults With Possible High or Low Genetic Risk for Type 2 Diabetes
Who can join
Ages 10 to 70 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Age 10-70 years * Prior participant of the UPenn Biobank or Center for Applied Genomics Biobank and agreed to be recontacted for future research. * Adults with BMI 25kg/m2 or higher, children and adolescents with BMI 85th percentile or higher Exclusion Criteria: * prior diagnosis of type 1, type 2, or secondary diabetes * use of medications that would impact glucose and insulin response such as steroids, metformin or other anti-diabetic medication * acute illness that may impact insulin and glucose dynamics * pregnancy * hypothalamic obesity or related genetic disorder of metabolism * recent systemic chemotherapy use * gastrointestinal impairment or surgery that may impact absorption * anemia * major organ system illness or any underlying condition requiring regular medication or treatment that could make implementation of the protocol or interpretation of the study results difficult * inability to comply with study protocol
About the study
This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.
What is being tested
- 75g glucose beverage (Glucola, Trutol, or similar brand) (other)
- DXA, whole body (other)
Sponsor: University of Pennsylvania · Participants: 100 · Started: Jun 17, 2019
Contact the study team
- Jessica R Wilson, MD, MS · Phone: 215 898-3389
Official record on ClinicalTrials.gov — NCT04024631
Locations in the U.S.
| Pennsylvania | Childrens Hospital of Philadelphia, Philadelphia (Not yet recruiting) University of Pennsylvania, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.